GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Hengrui Pharmaceuticals Co Ltd (SHSE:600276) » Definitions » Financial Strength

Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Financial Strength : 10 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Jiangsu Hengrui Pharmaceuticals Co Financial Strength?

Jiangsu Hengrui Pharmaceuticals Co has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

Jiangsu Hengrui Pharmaceuticals Co Ltd shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Jiangsu Hengrui Pharmaceuticals Co's interest coverage with the available data. Jiangsu Hengrui Pharmaceuticals Co's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.00. As of today, Jiangsu Hengrui Pharmaceuticals Co's Altman Z-Score is 47.29.


Competitive Comparison of Jiangsu Hengrui Pharmaceuticals Co's Financial Strength

For the Drug Manufacturers - General subindustry, Jiangsu Hengrui Pharmaceuticals Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Financial Strength falls into.



Jiangsu Hengrui Pharmaceuticals Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Jiangsu Hengrui Pharmaceuticals Co's Interest Expense for the months ended in Mar. 2024 was ¥0 Mil. Its Operating Income for the months ended in Mar. 2024 was ¥1,491 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥78 Mil.

Jiangsu Hengrui Pharmaceuticals Co's Interest Coverage for the quarter that ended in Mar. 2024 is

GuruFocus does not calculate Jiangsu Hengrui Pharmaceuticals Co's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Jiangsu Hengrui Pharmaceuticals Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Jiangsu Hengrui Pharmaceuticals Co's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 78.398) / 23990.136
=0.00

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Jiangsu Hengrui Pharmaceuticals Co has a Z-score of 47.29, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 47.29 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Hengrui Pharmaceuticals Co  (SHSE:600276) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Jiangsu Hengrui Pharmaceuticals Co has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.


Jiangsu Hengrui Pharmaceuticals Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Jiangsu Hengrui Pharmaceuticals Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Business Description

Traded in Other Exchanges
N/A
Address
No. 38, Huanghe Road, Economic, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222047
Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications. It specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.

Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Headlines

No Headlines